Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: A meta-analysis

Clinical Colorectal Cancer

Volumn 13, Issue 2, 2014, Pages 110-118

  Guo, Yuanbiao ^a   Shi, Min ^a   Shen, Xiaoheng ^a   Yang, Chen ^a   Yang, Liu ^a   Zhang, Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antineoplastic protocols; Colorectal neoplasms; Combination drug therapy; Neoplasm metastasis; Randomized controlled trial

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE;

ACUTE CORONARY SYNDROME; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOCYTE; META ANALYSIS; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONALCOHOLIC FATTY LIVER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84900510125     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.12.004     Document Type: Article

References (24)

1. A. Jemal, F. Bray, and M.M. Center et al. Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. R.J. Cersosimo Management of advanced colorectal cancer, part 2 Am J Health Syst Pharm 70 2013 491 506
3. C.H. Kohne, E. van Cutsem, and J. Wils et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986 J Clin Oncol 23 2005 4856 4865
4. L.B. Saltz, J.V. Cox, and C. Blanke et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group N Engl J Med 343 2000 905 914
5. J.Y. Douillard, D. Cunningham, and A.D. Roth et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
6. C.S. Fuchs, J. Marshall, and E. Mitchell et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 2007 4779 4786
7. C. Twelves Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials Eur J Cancer 38 suppl 2 2002 15 20
8. Y.Z. Patt, F.C. Lee, and J.E. Liebmann et al. Capecitabine plus 3-weekly irinotecan (xeliri regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results Am J Clin Oncol 30 2007 350 357
9. E. Bajetta, M. Di Bartolomeo, and L. Mariani et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma Cancer 100 2004 279 287
10. M.M. Borner, J. Bernhard, and D. Dietrich et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity Ann Oncol 16 2005 282 288
11. D.W. Rea, J.W. Nortier, and W.W. Ten Bokkel Huinink et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer Ann Oncol 16 2005 1123 1132
12. J. Souglakos, N. Ziras, and S. Kakolyris et al. Randomised phase II trial of capiri (capecitabine, irinotecan) plus bevacizumab vs folfiri (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (MCRC) Br J Cancer 106 2012 453 459
13. D. Pectasides, G. Papaxoinis, and K.T. Kalogeras et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis BMC Cancer 12 2012 271
14. E. Skof, M. Rebersek, and Z. Hlebanja et al. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial BMC Cancer 9 2009 120
15. M. Ducreux, A. Adenis, and J.P. Pignon et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) Eur J Cancer 49 2013 1236 1245
16. N. Silvestris, E. Maiello, and F. De Vita et al. Update on capecitabine alone and in combination regimens in colorectal cancer patients Cancer Treat Rev 36 suppl 3 2010 S46 S55
17. K. Holt Common side effects and interactions of colorectal cancer therapeutic agents J Pract Nurs 61 2011 7 20
18. A.P. Verhagen, H.C. de Vet, and R.A. de Bie et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus J Clin Epidemiol 51 1998 1235 1241
19. C.H. Köhne, J. De Greve, and J.T. Hartmann et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann Oncol 19 2008 920 926
20. F. Montagnani, A. Chiriatti, and S. Licitra et al. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer Clin Colorectal Cancer 9 2010 243 247
21. Irinotecan [package insert] 2008 Hospira Lake Forest, IL
22. H. Bleiberg, and E. Cvitkovic Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective Eur J Cancer 32A suppl 3 1996 S18 S23
23. C.S. Fuchs, M.R. Moore, and G. Harker et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 21 2003 807 814
24. J. Cortes, V. Calvo, and N. Ramirez-Merino et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis Ann Oncol 23 2012 1130 1137